Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 701–800 of 1,010
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Detecting the effect of genetic diversity on brain composition in an Alzheimer’s disease mouse model
Gurdon, B., Yates, S. C., Csucs, G., Groeneboom, N. E., Hadad, N., Telpoukhovskaia, M., Ouellette, A., Ouellette, T., O’Connell, K. M. S., Singh, S., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06242-1 · Cited by 15
Identification and Experimental Validation of Marker Genes between Diabetes and Alzheimer’s Disease
Huang, C., Wen, X., Xie, H., Hu, D., & Li, K. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8122532 · Cited by 15
“Usually, several nonspecific factors, such as age, vascular disease, infection, and environmental changes, are thought to play a role [2].”
BackgroundHossain, M. K., Ashraf, A., Islam, M. M., Sourav, S., & Shimul, M. M. H. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70162 · Cited by 19
Metabolome informs about the chemical exposome and links to brain health
Orešič, M., Karu, N., Zhao, H. N., Moseley, M. A., Hankemeier, T., Wishart, D. S., Dorrestein, P. C., Fiehn, O., Hyötyläinen, T., & Kaddurah‐Daouk, R. (2025) · Environment International · doi:10.1016/j.envint.2025.109741 · Cited by 18
“…and BBB damage, and neuronal apoptosis (Gauvrit et al., 2022; Babić Leko et al., 2023; Huat et al., 2019; Yu et al., 2024; Paglia et al., 2016; Breijyeh and Karaman, 2020; Colomina and Peris-Sampedro, 2017; Ariafar et al., 2023; Deng et al., 2023; Mutter et al., 2004; Rahman et al., 2020;…”
Zhao, X., Chen, X., Zhou, Z., Zheng, J., Lin, Y., Zheng, Y., Xu, R., Hu, S., & Cui, L. (2025) · MedComm · doi:10.1002/mco2.70395 · Cited by 15
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 19
PACAP: A promising disease-modifying target for Alzheimer's disease
Basri, R., Al-Kuraishy, H. M., Fawzy, M. N., Alruwaili, M., & Batiha, G. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124176 · Cited by 15
Model scenarios for cell cycle re-entry in Alzheimer's disease
Pandey, N., & Vinod, P. K. U. (2022) · iScience · doi:10.1016/j.isci.2022.104543 · Cited by 16
“Accordingly, various therapeutic approaches targeting the underlying molecular players have been tested (Breijyeh and Karaman, 2020; Liu et al., 2019).”
Yang, L., Liang, J., Zheng, Q., Zhou, L., Xiong, Y., Wang, H., & Yuan, J. (2022) · Pharmaceuticals · doi:10.3390/ph16010030 · Cited by 15
“Discussion AD is a chronic degenerative neurological disease, the clinical symptoms of which are memory loss, concentration loss, and dementia; the pathological manifestations are neuron loss, β-Amyloid protein precipitation, and entanglement of the nerve fibers caused by hyperphosphorylation of the tau protein [21].”
BackgroundAydin, B. O., Anıl, D. A., Demir, Y., & Alagöz, M. A. (2024) · Molecular Diversity · doi:10.1007/s11030-023-10774-9 · Cited by 15
“Alzheimer disease (AD) is a brain disease that gradually reduces one's capacity for remembering, thinking, and performing even the most principal tasks [17, 18].”
de Mello, J. E., Teixeira, F. C., dos Santos, A., Luduvico, K. P., Soares, M. S. P., Domingues, W. B., Campos, V. F., Tavares, R. G., Schneider, A., Stefanello, F. M., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04062-2 · Cited by 16
“The development and progression of AD has been associated with multifactorial interactions, including genetic, environmental and lifestyle factors [2, 3].”
Una Revisión Crítica sobre la Aplicación de Estimulación Cognitiva en el Contexto Gerontológico
Borrego-Ruiz, A. (2024) · Escritos de Psicología / Psychological Writings · doi:10.24310/escpsi.17.1.2024.18566 · Cited by 17
Yu, M.-H., Lim, J. S., Yi, H.-A., Won, K. S., & Kim, H. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137479 · Cited by 16
“Although the exact cause of AD has not been confirmed, its etiology is multifactorial and involves a complex interplay of genetic, environmental, and lifestyle factors [2,3].”
BackgroundFluca, A. L., Pani, B., Janjusevic, M., Zwas, D. R., Abraham, Y., Calligaris, M., Beltrami, A. P., Corgosinho, F. C., Marketou, M. E., D’Errico, S., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122911 · Cited by 16
Givian, H., & Calbimonte, J.-P. (2024) · IEEE Access · doi:10.1109/access.2024.3438081 · Cited by 15
“AD is considered a multifactorial disease but the scientists proposed the beta-amyloid (A β ) neuritic plaques and neurofibrillary tangles (called Tau proteins) as the main causes [10].”
BackgroundBenali, T., Laghmari, M., Touhtouh, J., Aanniz, T., Lemhadri, A., Daoudi, M. D., Bouyahya, A., Lee, L., Ullah, R., Alotaibi, A., et al. (2024) · Biochemical Systematics and Ecology · doi:10.1016/j.bse.2024.104880 · Cited by 15
Mechanism of Metal Complexes in Alzheimer’s Disease
Yi, L. I. U., Ma, J., Zhang, Q., Wang, Y., & Sun, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211873 · Cited by 18
Hosseinpour-Mashkani, S. M., Bishop, D., Westerhausen, M. T., Adlard, P. A., & Golzan, M. (2024) · Metallomics · doi:10.1093/mtomcs/mfae053 · Cited by 18
“Alzheimer’s disease (AD), a progressive neurodegenerative disorder marked by memory loss and behavioural changes, is often linked with aging [1 ].”
Hongen, T., Sakai, K., Ito, T., Qin, X., & Sone, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312523 · Cited by 15
Fang, H., Tian, H., Liu, J., Peng, T., & Wang, D. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.011 · Cited by 15
Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease
Abualassal, Q. I. A., Abudayeh, Z. H. M., Sirhan, A. Y., & Mkia, A. (2025) · Molecules · doi:10.3390/molecules30030555 · Cited by 17
“…and potentiality of 2,4-disubstituted quinazoline derivatives for treating AD, additional research on these compounds is essential [34,35]. the e ffi cacy and potentiality of 2,4-disubstituted quinazoline derivatives for treating AD, additional research on these compounds is essential [34,35].”
Kuştan, F., Sıcak, Y., Mali, S. N., Chaudhari, S. Y., Öztürk, M., & Tok, F. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143637 · Cited by 23
Li, G., Liang, R., Lian, Y., & Zhou, Y. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147878 · Cited by 15
Bhargava, A., Sandoval-Castellanos, A. M., Shah, S. S., & Ning, K. (2022) · Interface Focus · doi:10.1098/rsfs.2022.0040 · Cited by 15
Is Mitochondria DNA Variation a Biomarker for AD?
Gao, R., & Ma, S. L. (2022) · Genes · doi:10.3390/genes13101789 · Cited by 15
“Patients have trouble in thinking and making decisions, difficulty in performing familiar tasks and increased memory loss and eventually progress to cognitive impairment [6].”
BackgroundInfluentialSzczurowska, E., Szánti‐Pintér, E., Chetverikov, N., Randáková, A., Kudová, E., & Jakubík, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010507 · Cited by 18
Meng, S., Chen, H., Deng, C., & Meng, Z. (2023) · Neurotoxicity Research · doi:10.1007/s12640-022-00626-z · Cited by 17
“Even though AD is a public health issue, as of now, there is only two classes of drugs approved to treat AD, including inhibitors to cholinesterase enzyme (naturally derived, synthetic and hybrid analogs) and antagonists to N-methyl d-aspartate (NMDA) (Breijyeh and Karaman 2020; Thoe et al.”
BackgroundZhang, H., Li, X., Wang, X., Xu, J., Elefant, F., & Wang, J. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12313 · Cited by 19
How Closely Does Induced Agarwood’s Biological Activity Resemble That of Wild Agarwood?
Ma, S., Huang, M., Fu, Y., Qiao, M., & Li, Y. (2023) · Molecules · doi:10.3390/molecules28072922 · Cited by 15
“More frighteningly, the number is predicted to rise to 152 million by 2050, and the annual cost of treating patients is up to USD 1 trillion, making it a global problem [23].”
BackgroundProposing novel natural compounds against Alzheimer’s disease targeting acetylcholinesterase
Girgin, M., Işık, S., & Kantarci-Carsibasi, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284994 · Cited by 18
“Although it is known that currently there are about 50 million ADs in the world, these numbers will continue to increase in the coming years and it is expected to reach 152 million by 2050 [4, 5].”
BackgroundCui, K., Li, C., & Fang, G. (2023) · Life · doi:10.3390/life13051204 · Cited by 16
“Similar to Parkinson’s disease (PD) and Huntington’s disease (HD), it is a degenerative disease of the nervous system and has long represented a great challenge in the field of public health [1].”
BackgroundMulti-target regulatory mechanism of Yang Xin Tang − a traditional Chinese medicine against dementia
Lo, T. Y., Chan, A. S. L., Cheung, S. T., Yung, L. Y., Leung, M. M. H., & Wong, Y. H. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00813-w · Cited by 18
“Current medications, including acetylcholinesterase (AChE) inhibitors and N-methyl D-aspartate (NMDA) antagonists [1, 2], can impede disease progression and are primarily effective in the early stages of AD.”
BackgroundSanadgol, N., Amini, J., Beyer, C., & Zendedel, A. (2023) · Biomolecules · doi:10.3390/biom13091401 · Cited by 17
“Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the loss of brain cells and is the leading cause of dementia, accounting for over 80% of dementia cases [1].”
Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives
Zhang, Y., Zhang, J., Wang, J., Chen, H., Ouyang, L., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114668 · Cited by 16
Nong, W., Bao, C., Chen, Y., & Wei, Z. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6723 · Cited by 14
“AD is predominately associated with accumulation of amyloid-beta (Aβ), hyperphosphorylation of tau protein, increased oxidative stress and mitochondria dysfunction, as well as environmental risks, leading to loss of synapses, neurons cognitive impairment, and even death at the late stage [2-4].”
BackgroundLohnes, B. J., Goff, A. J., Hartwig, U. F., & Poddar, N. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-12186-1 · Cited by 15
Park, J., Gong, J. H., Chen, Y., Nghiem, T.-H. T., Chandrawanshi, S., Hwang, E., Yang, C. H., Kim, B.-S., Park, J. W., Ryter, S. W., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109325 · Cited by 14
Ranganathan, R., Sapozhnikov, G., Wang, N., Li, S., & Song, Y. (2023) · Translational Medicine of Aging · doi:10.1016/j.tma.2023.06.004 · Cited by 14
Bayesian inference and dynamic prediction for multivariate longitudinal and survival data
Zou, H., Zeng, D., Xiao, L., & Luo, S. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1733 · Cited by 21
Demirel, G., Sanajou, S., Yirün, A., Çakır, D. A., Berkkan, A., Baydar, T., & Erkekoğlu, P. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4564 · Cited by 18
“The drugs used for AD only provide palliative therapy and delay the onset of symptoms (Breijyeh & Karaman, 2020).”
MethodAlzahrani, A. Y. A., Ullah, H., Bhat, M. A., Rahim, F., Al-Wesabi, E. O., & Alanazi, T. Y. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137167 · Cited by 18
The Role of Resveratrol in Alzheimer's Disease: A Comprehensive Review of Current Research
Kumar, S., Saha, S., Sharma, B., Singh, S., Shukla, P., Mukherjee, S., Agarwal, M., Singh, K., & Singh, T. (2023) · Current Functional Foods · doi:10.2174/0126668629269244231127071411 · Cited by 15
Ayuda‐Durán, B., Garzón‐García, L., González‐Manzano, S., Santos‐Buelga, C., & Gonzaléz‐Paramás, A. M. (2024) · Antioxidants · doi:10.3390/antiox13010079 · Cited by 17
“Although its etiology is unknown, the development in the brain of extracellular β -amyloid (A β ) plaques and intracellular protein Tau aggregation forming neurofibrillary tangles are hallmarks of this neuropathology [2].”
BackgroundRen, T., Chen, Z. B., Xie, J., Tan, S., & Zhu, Y. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106046 · Cited by 14
Umar, T. P., Jain, N., Stevanny, B., Javed, B., Priandhana, A., Siburian, R., & Kostiks, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27425 · Cited by 15
“Multiple factors, such as genetics, the environment, and lifestyle contribute in the development and progression of AD [3].”
BackgroundSchreiner, T. G., Croitoru, C. G., Hodorog, D. N., & Cuciureanu, D. I. (2024) · Biomedicines · doi:10.3390/biomedicines12051096 · Cited by 15
“Moreover, the underlying pathophysiological mechanisms responsible for disease progression are also merely partially understood [8].”
BackgroundAlzheimer's disease and herpes viruses: Current events and perspectives
Pinchera, B., Filippo, I. D., Cuccurullo, F., Salvatore, E., & Gentile, I. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2550 · Cited by 20
Reich, N., Allsop, D., Parkin, E. T., & Dawson, N. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18477 · Cited by 15
López‐Cerdán, A., Andreu, Z., Hidalgo, M. R., Soler-Sáez, I., Porlan, A., Pozo‐Morales, M., León, S., de la Iglesia-Vayá, M., Mikozami, A., Guerini, F. R., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106605 · Cited by 14
Therapeutic potential of fucoidan in central nervous system disorders: A systematic review
Yang, J., Zhao, H., & Qu, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134397 · Cited by 16
Toraman, G. Ö., Bayrakdar, A., Oğuz, E., Beytur, M., Türkan, F., Manap, S., Aras, A., & Yüksek, H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139733 · Cited by 14
Esbensen, A. J., Schworer, E. K., & Hartley, S. L. (2024) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-66932-3_13 · Cited by 15
Fisher, R. M. A., & Torrente, M. P. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1456052 · Cited by 20
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 16
“Memantine is an antagonist of the N-methyl D-aspartate receptor and helps manage symptoms during the moderate-to-severe stages [4].”
Nuclear podosomes regulates cellular migration in Tau and Alzheimer’s disease
Qureshi, T., Chandrashekar, M., Ananthanarayana, V., Kumarappan, M., Rangappa, N., Velmurugan, G., & Chinnathambi, S. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.09.009 · Cited by 27
Ju, I. G., Lee, S., Im, H., Kim, J.-H., Eo, H., & Oh, M. S. (2024) · GeroScience · doi:10.1007/s11357-024-01388-6 · Cited by 14
“Although the mechanism of AD pathogenesis is not fully understood, the accumulation of β-amyloid (Aβ) and tau and sustained neuroinflammation are considered to be the major factors implicated in neuronal cell damage, and subsequent brain atrophy and memory decline [1, 3].”
Ohal, H. S., & Mantri, S. (2024) · Measurement Sensors · doi:10.1016/j.measen.2024.101403 · Cited by 21
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
“It has been observed that in patients with AD, the loss of synapses is closely related to the loss of cholinergic neurotransmission, which in turn correlates with the low levels of ACh observed in Alzheimer’s patients [19,152,154,155].”
Dincel, E. D., Kuran, E. D., Demir, Y., Sucu, B. O., Gülçın, İ., & Ulusoy-Güzeldemirci, N. (2025) · ChemistrySelect · doi:10.1002/slct.202405876 · Cited by 14
Zhang, Y., Gu, Q., Li, Y., Li, J., Han, Y., Feng, L., Qin, X., Zhang, J., Zhou, Z., & Chang, X. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138972 · Cited by 15
Kumari, S., Begum, M. Y., Chinglenthoiba, C., Aran, K. R., Panda, S. P., Abomughaid, M. M., Lakhanpal, S., Avinash, D., Jha, N. K., & Gupta, R. V. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05174-z · Cited by 18
“AD, the most prevalent type of dementia, is a degenerative neurological disorder characterized by memory impairment [119].”
Mouazen, B., Bellakhdar, O., Ennair, A., Laghdaf, K., Bendaouia, A., Abdelwahed, E. H., & de Marco, G. (2025) · Sensors · doi:10.3390/s25185690 · Cited by 14
“It causes mainly memory loss, and is common among older people; today, more than 50 million people have Alzheimer’s around the world [3,4].”
Subcommissural Organ-Spondin-Derived Peptide Restores Memory in a Mouse Model of Alzheimer’s Disease
Douce, J. L., Delétage, N., Bourdès, V., Lemarchant, S., & Godfrin, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.651094 · Cited by 15
Lazar, S. V., Mor, S., Wang, D., Goldbloom‐Helzner, L., Clark, K. C., Hao, D., Farmer, D. L., & Wang, A. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1541 · Cited by 15
An Interactive Review on the Role of Tocotrienols in the Neurodegenerative Disorders
Naomi, R., Shafie, N. H., Kaniappan, P., & Bahari, H. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.754086 · Cited by 17
“AD can be categorized into 4 stages; (1) preclinical stage of AD, (2) Mild Cognitive impairment due to AD and (3) moderate AD and (4) Severe AD (23).”
BackgroundEissa, K. I., Kamel, M. M., Mohamed, L. W., Galal, M. A., & Kassab, A. E. (2022) · Drug Development Research · doi:10.1002/ddr.21968 · Cited by 15
Sticker-and-spacer model for amyloid beta condensation and fibrillation
Connor, J. P., Quinn, S. D., & Schaefer, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.962526 · Cited by 17
“A major pathogenic hallmark in AD brains is the presence of extracellular neurotoxic plaques made up of amyloid beta (Aβ) (Stelzmann et al., 1995; Breijyeh and Karaman, 2020).”
BackgroundOverexpression of fibroblast growth factor 13 ameliorates amyloid-β-induced neuronal damage
Zhu, H., Li, R., Xiao, L., Zhang, T., & Ren, D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.357902 · Cited by 16
“The amyloid hypothesis and cholinergic hypothesis are the two main AD hypotheses (Breijyeh and Karaman, 2020).”
BackgroundInfluentialZBTB20-AS1 promoted Alzheimer's disease progression through ZBTB20/GSK-3β/Tau pathway
Wang, Y., Cai, M., Lou, Y., Zhang, S., & Liu, X. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.107 · Cited by 14
Rasheed, A., Zaheer, A. B., Munawwar, A., Sarfraz, Z., Sarfraz, A., Robles‐Velasco, K., & Chérrez-Ojeda, I. (2022) · Life · doi:10.3390/life13010001 · Cited by 15
Naki, T., Matshe, W. M. R., Balogun, M. O., Ray, S. S., Egieyeh, S. A., & Aderibigbe, B. A. (2023) · Journal of Microencapsulation · doi:10.1080/02652048.2023.2167011 · Cited by 14
Protein-Balanced Dietary Habits Benefit Cognitive Function in Japanese Older Adults
Sakurai, K., Okada, E., Anzai, S., Tamura, R., Shiraishi, I., Inamura, N., Kobayashi, S., Sato, M., Matsumoto, T., Kudo, K., et al. (2023) · Nutrients · doi:10.3390/nu15030770 · Cited by 16
“Alzheimer’s disease (AD), the most common cause of dementia, has no treatment to halt or reverse its progression, although some treatments temporarily improve symptoms [4].”
BackgroundGalizzi, G., Deidda, I., Amato, A., Calvi, P., Terzo, S., Caruana, L., Scoglio, S., Mulè, F., & Carlo, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054731 · Cited by 15
“This pathology is characterized by progressive cognitive and memory loss that ultimately ends in dementia [3].”
BackgroundRoncero-Parra, C., Torres, A. P., Sánchez-Reolid, R., Mateo-Sotos, J., & Borja, A. L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26298 · Cited by 14
Advances of therapy for Alzheimer's disease: An updated review
Mei, C., Zhan, J., Zhu, S., Zhang, Y., Xiong, C., Wang, J., Xu, Y. J., Zhong, H., & Cheng, J. (2024) · Brain‐X · doi:10.1002/brx2.68 · Cited by 16
Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview
Llanes, L. C., Kuehlewein, I., de França, I. V., da Silva, L. V., & Júnior, J. W. D. C. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220803113411 · Cited by 14
Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases
Bruno, F., Laganà, V., Lorenzo, R. D., Bruni, A. C., & Maletta, R. (2022) · Biomedicines · doi:10.3390/biomedicines10092288 · Cited by 15
“Alzheimer’s disease (AD) is the most widespread type of dementia, clinically characterized by both cognitive and non-cognitive symptoms [40].”
BackgroundDemirbas, M., Hahn‐Pedersen, J. H., & Jørgensen, H. L. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00493-6 · Cited by 14
“For instance, AD is reported as a single value despite encompassing mild, moderate and severe dementia, with mild cognitive impairment preceding these stages of AD [53].”
BackgroundAn optimistic approach to nanotechnology in Alzheimer's disease management: An overview
Tiwari, V., Tiwari, A., Sharma, A., Kumar, M., Kaushik, D., & Sagadevan, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104722 · Cited by 14
Shuai, Z., Jingya, Z., Qing, W., Qiong, W., Chen, D., Guodong, S., & Zhang, Y. (2023) · The journal of nutrition health & aging · doi:10.1007/s12603-023-1963-4 · Cited by 14
“The participants were further excluded if they (1) were not able to finish the cognitive function assessment or sedentary behavior assessment (n = 71) or (2) had any missing covariate data (n = 59).”
BackgroundMethodGao, S., Yue, J., Li, X.-L., Li, A., Cao, D., Han, S.-W., Wei, Z., Yang, G., & Zhang, Q. (2023) · Medicine · doi:10.1097/md.0000000000034994 · Cited by 13
“It is a complex and irreversible neurologic disease that causes cognitive impairment.[3,4] Amnestic mild cognitive impairment (aMCI) is a condition that is typically marked by memory problems that go beyond what is expected with normal aging.”
BackgroundKim, D. H., Chegal, W., Diware, M. S., Choi, W., Lee, N. H., Cho, Y. J., & Cho, H. M. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134588 · Cited by 13
Murray‐Smith, H., Barker, S., Barkhof, F., Barnes, J., Brown, T. M., Captur, G., Cartlidge, M. R. E., Cash, D. M., Coath, W., Davis, D. H. J., et al. (2024) · BMC Neurology · doi:10.1186/s12883-023-03465-3 · Cited by 13
“The biggest known risk factor for dementia is age, and AD and cerebrovascular disease are the most common causes of dementia and cognitive decline [8, 9].”
BackgroundPharmacological Approaches and Herbal Interventions for Alzheimer's Disease
Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024) · The Natural Products Journal · doi:10.2174/0122103155275266231123090138 · Cited by 16
Genomic Insights into Dementia: Precision Medicine and the Impact of Gene-Environment Interaction
Tripathi, A., Pandey, V. K., Sharma, G., Sharma, A. R., Taufeeq, A., Jha, A. K., & Kim, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0322 · Cited by 16
“The importance of considering additional risk factors, such as age, sex, and familial history of dementia, when analyzing an individual's unique risk signature has become even more apparent [95].”
BackgroundMethodInfluentialWu, L., Guo, X., Gao, Y., Yu, W., Qin, W., Kuang, H., & Su, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130804 · Cited by 15
McArthur, N., Kang, B., Moctezuma, F. G. R., Shaikh, A. T., Loeffler, K., Bhatt, N. N., Kidd, M., Zupancic, J. M., Desai, A. A., Djeddar, N., et al. (2024) · Biotechnology Progress · doi:10.1002/btpr.3463 · Cited by 13
“5 Neurodegenerative diseases disproportionately affect older adults, and their prevalence will continue to grow as the life expectancy and size of the human population increase.”
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Hroudová, J., & Fišar, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111069 · Cited by 13
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Lamisa, A. B., Ahammad, I., Bhattacharjee, A., Hossain, M. U., Ishtiaque, A., Chowdhury, Z. M., Das, K. C., Salimullah, M., & Keya, C. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-75431-z · Cited by 15
“Furthermore, Alzheimer's disease (AD) is a matter of significant public health concern on a global scale, both in the United States and in several other countries around the world [5], [6].”
BackgroundNovel techniques for early diagnosis and monitoring of Alzheimer’s disease
Parul, P., Singh, A. K., & Shukla, S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2415985 · Cited by 17
“Aphasia, apraxia and agnosia are the important signs existing with general cognitive symptoms such as poor judgment, difficulty in making decisions and difficulty in orienting oneself [8].”
Zhang, X., Wu, M., Cheng, L., Cao, W., Liu, Z., Yang, S., & Kim, M. S. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02756-6 · Cited by 16
“AD deprives people of their independence and is the fi fth leading cause of death [127 – 129].”
High-resolution pressure sensing insole via sensitivity-tunable fibers towards gait recognition
Xia, Y. Y., Zhang, S., Qu, Y., Zhang, S., Zhang, X., Zhao, J., Li, X., Zeng, H., Wang, H., Liu, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159841 · Cited by 13
Zeng, Y., Liu, B., Zhou, L., Zeng, W., Tian, X., Jiang, J., & Dai, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2467180 · Cited by 17
“Therefore, The inhibition of hydrolysis of acetylcholine by acetylcholinesterase (AChE) is a breakthrough in AD treatment [11,12].”
Promising Natural Remedies for Alzheimer’s Disease Therapy
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2025) · Molecules · doi:10.3390/molecules30040922 · Cited by 14
“Furthermore, compared to traditional pharmaceuticals, which might result in negative reactions including gastrointestinal distress or neuropsychiatric symptoms, natural products are frequently seen to be safer and have fewer side effects [14].”
InfluentialSelf-citationArıkan, F. B., Çetintaş, D., Aksoy, A., & Yıldırım, M. (2025) · Biomedicines · doi:10.3390/biomedicines13082017 · Cited by 17
“Negative lesions are marked by significant brain atrophy resulting from neuronal, neuropil, and synaptic loss [1,2].”
Alvite‐Piñeiro, T., López‐López, M., Regueiro, U., Peleteiro, J. M. P., Sobrino, T., & Lema, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175963 · Cited by 13
“NFTs are abnormal filaments of hyperphosphorylated tau protein that pair and he-lically coil in the cytoplasm of neurons [14].”
Nagpal, D., Nema, S., Nagpal, S., Pandey, M. M., Kaushik, D. K., & Kathuria, H. (2025) · Antioxidants · doi:10.3390/antiox14091078 · Cited by 19
“AD is the most common type of dementia, and it develops by forming neuritic plaques and neurofibrillary tangles [257].”
Genetically altered animal models forATP1A3-related disorders
Ng, H. W. Y., Ogbeta, J. A., & Clapcote, S. J. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048938 · Cited by 14
“…on other neurological disorders, such as Alzheimer ’ s disease, have shown that therapeutics that are disease modifying in mice are not necessarily disease modifying in human patients (Breijyeh and Karaman, 2020), perhaps reflecting some intrinsic physiological differences between humans and mice.”
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.